Pre-clinical analysis of the Cdk4/6 inhibitor Palbociclib in Her2-positive breast cancer.
Pre-clinical analysis of the Cdk4/6 inhibitor Palbociclib in Her2-positive breast cancer.
- 2017
Poster presented at
Poster presented at